Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided:	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.		It wasn't used in the experiment

Cell materials	Yes (indicate where provided:	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	Melanoma cancer cell lines HS294T were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences (Shanghai, China).	
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		It wasn't used in the experiment

Experimental animals	Yes (indicate where provided:	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		It wasn't used in the experiment
Animal observed in or captured from the field: Provide species, sex and age where possible		It wasn't used in the experiment
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID		It wasn't used in the experiment

Plants and microbes	Yes (indicate where provided:	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		It wasn't used in the experiment
Microbes: provide species and strain, unique accession number if available, and source		It wasn't used in the experiment

Human research participants	Yes (indicate where provided:	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		It wasn't used in the experiment
Provide statement confirming informed consent obtained from study participants.		It wasn't used in the experiment
Report on age and sex for all study participants.		It wasn't used in the experiment

Design

Study protocol	Yes (indicate where provided:	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.		It wasn't used in the experiment

Laboratory protocol	Yes (indicate where provided:	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.		It wasn't used in the experiment

Experimental study design (statistics details)	Yes (indicate where provided:	n/a
State whether and how the following have been done**, or** if they were not carried out.		It wasn't used in the experiment
Sample size determination		It wasn't used in the experiment
Randomisation		It wasn't used in the experiment
Blinding		It wasn't used in the experiment
Inclusion/exclusion criteria		It wasn't used in the experiment

Sample definition and in-laboratory replication	Yes (indicate where provided:	n/a
State number of times the experiment was replicated in laboratory		It wasn't used in the experiment
Define whether data describe technical or biological replicates		It wasn't used in the experiment

Ethics	Yes (indicate where provided:	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		It wasn't used in the experiment
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		It wasn't used in the experiment
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		It wasn't used in the experiment

Dual Use Research of Concern (DURC)	Yes (indicate where provided:	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		It wasn't used in the experiment

Analysis

Attrition	Yes (indicate where provided:	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.		It wasn't used in the experiment

Statistics	Yes (indicate where provided:	n/a
Describe statistical tests used and justify choice of tests.	Statistical analysis, Kaplan-Meier survival analyses, and independent sample *t*-tests were performed using the software SPSS version 23.0 (IBM Corp., Armonk, NY, USA). A P value <0.05 was considered statistically significant.	

Data Availability	Yes (indicate where provided:	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		It wasn't used in the experiment
If data are publicly available, provide accession number in repository or DOI or URL.		It wasn't used in the experiment
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	The GEPIA is a tool created by Dr. Zhang with his team at the lab of Peking University, adapting data from The Cancer Genome Atlas (TCGA) database. This paper used GEPIA to research the expression of UCK2 in a variety of tumors, and probe into the prognosis of melanoma expression-related UCK2.	

Code Availability	Yes (indicate where provided:	n/a
For all newly generated code and software essential for replicating the main findings of the study:		It wasn't used in the experiment
State whether the code or software is available.		It wasn't used in
If code is publicly available, provide accession number in repository, or DOI or URL.		It wasn't used in the experiment

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: https://dx.doi.org/10.21037/atm-21-2906